百濟神州宣佈將在2020年美國臨牀腫瘤學會(ASCO)年會上公佈多項臨牀數據
來源：百濟神州
北京時間2020年4月30日，百濟神州(納斯達克代碼：BGNE；香港聯交所代碼：06160)，是一家處於商業階段的生物科技公司，專注於用於癌症治療的創新型分子靶向和腫瘤免疫藥物的開發和商業化。公司今日宣佈將在2020年美國臨牀腫瘤學會(ASCO)年會上在一項口頭報告以及三項海報展示中公佈其BTK抑制劑BRUKINSA™(澤布替尼)以及抗PD-1抗體百澤安®(替雷利珠單抗)的臨牀數據。本次ASCO年會將於2020年5月29日至31日舉行。
>>>> 口頭報告
標題：
ASPEN: Results of a Phase III Randomized Trial of Zanubrutinib Versus Ibrutinib for Patients with Waldenström Macroglobulinemia (WM)
ASPEN臨牀試驗：澤布替尼對比伊布替尼用於治療華氏巨球蛋白血癥(WM)患者的3期隨機臨牀試驗結果
摘要編號：8007
分會場標題：
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
血液惡性腫瘤 – 淋巴瘤及慢性淋巴細胞白血病
第一作者：
Constantine S. Tam，內外全科醫學士、醫學博士(澳大利亞St. Vincent醫院)
>>>> 海報展示
標題：
Three-Year Follow-up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single-Agent Zanubrutinib
澤布替尼單藥治療初治或既往接受過治療的華氏巨球蛋白血癥(WM)患者的三年隨訪結果
摘要編號：8051
海報編號：384
分會場標題：
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
血液惡性腫瘤 – 淋巴瘤及慢性淋巴細胞白血病
第一作者：
Constantine S. Tam，內外全科醫學士、醫學博士(澳大利亞St. Vincent醫院)
標題：
Phase 3 Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First line (1L) Treatment for Advanced Squamous Non-Small Cell Lung Cancer (sq NSCLC)
百澤安®(替雷利珠單抗)聯合化療對比僅用化療用於治療一線晚期鱗狀非小細胞肺癌(NSCLC)患者的3期臨牀試驗
摘要編號：9554
海報編號：320
分會場標題：
Lung Cancer—Non-Small Cell Metastatic Poster Session
肺癌 – 轉移性非小細胞癌海報展示分會場
第一作者：
王潔，醫學博士(中國醫學科學院腫瘤醫院)
標題：
Association Between Immune and Tumor Gene Signatures with Response or Resistance to Tislelizumab Monotherapy or in Combination with Chemotherapy in Gastroesophageal Adenocarcinoma
胃食管腺癌患者接受百澤安®(替雷利珠單抗)單藥或聯合化療治療後產生緩解或抗藥是否與免疫及腫瘤基因特徵相關的研究
摘要編號：3115
海報編號：179
分會場標題：
Developmental Therapeutics—Immunotherapy Poster Session
研發階段療法 – 免疫腫瘤海報展示分會場
第一作者：
徐建明，醫學博士(中國解放軍總醫院)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
